Les Recommandations Thérapeutiques Les Publications Résumés des Protocoles GERCOR Le Courrier du Gercor Les Newsletters Autres Protocoles : Résumés Plan Accueil Nous contacter Quitter dictionnaire médical

Les Publications
Communications orales ou par affiches dans des congrès avec comité de sélection en langue anglaise
Publications dans des revues avec comité de lecture en langue anglaise
Publications dans des revues avec comité de lecture en langue française
GERCOR : ASCO 2002

toutes les rubriques



Communications orales ou par affiches dans des congrès avec comité de sélection en langue anglaise
Abstracts en anglais
Abstracts en anglais

C Tournigand, C Louvet, JL Molitor, N Dehni, V Lejeune, A Sezeur, A Pigne, L Marpeau, J Cady, A de Gramont. Long-term survival with consolidation intraperitoneal chemotherapy (IP)  in advanced ovarian carcinoma (AOC). Eur J Cancer 2001; 37 (suppl 6):S320 (abst 1188).

 

M Hebbar, C Tournigand, G Lledo, M Mabro, T André, T Aparicio, M Flesch, C Varette, A de Gramont for the GERCOR. Phase II evaluation of an alternated FOLFOX/FOLFIRI regimen in patients with resistnt metastatic colorectal cancer (CRC). Eur J Cancer 2001; 37 (suppl 6):S308 (abst 1138).

 

E Achille, C Tournigand, T André, G Lledo, M Flesch, G Ganem, P Colin, B Landi, C Couteau, A de Gramont. FOLFIRI then FOLFOX Versus FOLFOX then FOLFIRI in metastatic Colorectal Cancer (MCRC): Result of a phase  III trial. Eur J Cancer 2001; 37 (suppl 6):S289 (abst 1067).

 

T André, C Louvet, O Rosmorduc, P Artru,  F Selle  , C Tournigand  , ML Garcia  , F Maindrault, D Avenin ,  S Provent  and A de Gramont  for the GERCOR. A Phase II Study Of Gemcitabine And Oxaliplatin (GEMOX) In Advanced Biliary Adenocarcinoma (ABA). Preliminary Results. Eur J Cancer 2001; 37 (suppl 6):S19 (abst 60).

 

Maindrault-Goebel F, Louvet C, André T, Gilles V, Artru P, Tournigand C, Garcia M, Gervais H, Carola E, Krulik M and de Gramont A. Time to disease control (TDC) to evaluate the impact on survival of three chemotherapy lines in metastatic colorectal cancer (MRC) based on 5-Fluorouracil, oxaliplatin and irinotecan (GERCOR). Proc Am Clin Oncol 2001; 20:146a (abst 581).

 

Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, Dupont-André G and de Gramont A. Gemcitabine-oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC) : a multicenter phase II study. Proc Am Clin Oncol 2001; 20:127a (abst 506).

 

Tournigand C, Louvet C, Quinaux E, André T, Achille E, Lledo G, Flesch M, Ganem G, Landi B, Colin P, Denet C, Mery-Mignard D, Risse M.L, Buyse M and de Gramont A. FOLFIRI Followed by FOLFOX Versus FOLFOX Followed by FOLFIRI in metastatic Colorectal Cancer (MCRC). Proc Am Clin Oncol 2001; 20:124a (abst 494).

 

André T, Hammel P, Selle F, Louvet C, Deniaud-Alexandre E, Landi B, Cattan S, Gligorov J, Soubrane D, Touboul E and Balosso J. Multicentric GERCOR feasability study of bimonthly combination of leucovorin-5FU and gemcitabine (6 cycles) followed by chemoradiotherapy (CRT) with 5FU for locally advanced non metastatic pancreatic adenocarcinoma. Proc Am Clin Oncol 2001; 20:15a (abst 616).

 

Terrioux P, Beerblock K, Kanouï A, Colin P, Molitor J-L, Picavet B, Vannetzel J-M, Kayitalire L. Final results of a GERCOR phase I/ II study in chemonaive patients with advanced non small cell lung cancer (NSCLC) treated with a bimonthly Gemcitabine (G) plus Cisplatin (P) regimen. Proc Am Clin Oncol 2001 ; 20 : 263b (abst 2803).

 

Molitor JL, Louvet C, Deniaud E, Lotz JP, Carola E, Bachmeyer C, Varette C, Ganansia V, Tournigand C, Touboul E, Krulik M, de Gramont A. Phase II trial of sequential docetaxel-cisplatin-epirubicin regimen as first-line chemotherapy in advanced ovarian cancer : safety and surgical responses. Am Soc Clin Oncol, 2000 ; 19 : 398a (abst 1574).

 

Mabro M, André T, Louvet C, Carola E, Beerblock K, Krulik M, de Gramont A. Bimonthly leucovorin, 5FU infusion and hydroxyurea followed by CPT-11 (FOLFIRI2)  in pretreated patients with métastatic colorectal cancer. Am Soc Clin Oncol, 2000 ; 19 : 294a (abst 1151).*

 

Maindrault-Goebel F, Louvet C, Carola E, Gilles V, Lotz JP, Izrael V, Krulik M, de Gramont A. Oxaliplatin reintroduction in patients pretreated with leucovorin, 5FU and oxaliplatin for metastatic colorectal cancer. A GERCOR study. Am Soc Clin Oncol, 2000 ; 19 : 255a (abst 990).

 

Garcia ML, Gilles V, Louvet C, Defrance R, Tournigand C, Artru P, Maindrault-Goebel F, de Gramont A, Krulik M. Biweekly irinotecan combined with raltitrexed treatment in heavily pretreated patients with advanced colorectal cancer : a feasibility study. Am Soc Clin Oncol, 2000 ; 19 : 254a (abst 987).

 

Terrioux P, Beerblock K, Kanouï A, Molitor J-L, Picavet B, Vannetzel J-M, Kayitalire L, Colin P. Gemcitabine administered bimonthly in chemonaive patients with advanced non small cell lung cancer (NSCLC), stage IIIB or IV: Preliminary results of a phase I/ II study for GERCOR co-operative group. Ann Oncol 2000 ;11(suppl 4):114 (abst 524p).

 

Maindrault-Goebel F, Louvet C, André T, Carola E, Gilles V, Garcia M, Lotz J.P, Izraël V, Krulik M, de Gramont A. Oxaliplatin reintroduction in patients pretreated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer (MCRC). Ann Oncol 2000 ;11(suppl 4):50 (abst 216p).

 

Tournigand C, Achille E, Lledo G, Flesh M, Risse M.L, Ganem G, Landi B, Coin P, André T, de Gramont A. FOLRIRI followed by FOLFOX or FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC). Preliminary results of a randomized phase III study of the GERCOR. Ann Oncol 2000 ;11(suppl 4):43(abst 1870).

 

Tournigand C, Louvet C, André T, Achille E, Llebo G, Flesch M, Ganem G, Landi B, Risse M.L, Lotz V, Colin P, de Gramont A. FOLFIRI followed by FOLFOX or FOLFOX followed by FOLFIRI in metastatic colorectal cancer : which is the best sequence ? Safety and preliminary efficacy results of a randomized phase III study. Proc Am Clin Oncol 2000 ;245a (abst 949).

 

André T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Biliau V, Buyse M and de Gramont A. Toxicity report of a phase III trial (GERCOR C96.1) comparing bimonthly LV5FU2 to monthly 5FU – Leucovorin high dose (LV hd) in patients with Dukes B and C colon cancer. Proc Am Clin Oncol 2000 ;19:256a (abst 996).

 

André T, Louvet C. Phase II docetaxel epirubucin in second line for gastric cancer. 7th Franco- Japaness meeting on Clinical Cancer Research, 17/9/1999, Villejuif.

 

Molitor JL, Carrat F, Louvet C, Drolet Y, Demuynck B, de Gramont A, Krulik M. The prognosis of epithelial ovarian cancer in women over 70 : a study of 185 patients. Am Soc Clin Oncol, 1999 ; 18 : 578a (abst 2232).

 

Gilles-Amar V, Garcia ML, Sebille A, Maindrault-Goebel F, Louvet C, Beerblock K, Krulik M, de Gramont A. Evolution of severe sensory neuropathy with oxaliplatin combined to the bimonthly 48 hour leucovorin and 5-fluorouracil regimens (FOLFOX) in métastatic colorectal cancer . Am Soc Clin Oncol, 1999 ; 18 : 246a (abst 944).

 

André T, Colin P, Louvet C, de Gramont A. Overview of GERCOR colo-rectal cancer trials. Joint meeting EORTC - FFCD Liver and gastro-intestinal Tract Cancer. June 23-26, 1999 ; Paris.

 

André T, Balosso J, Louvet C, Hannoun L, Houry S, Huguier M, Parc R, Touboul E and Izraël V. Phase II trial of combined radiotherapy and chemotherapy as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinome. Bilio pancreatic malignancy : from gene to cure. February 4-5, 1999 ; Amsterdam.

 

André T, Louvet C, Ychou M, Gamelin E, Mousseau M, Carola E, Assadourian S, de Gramont A. Docetaxel-Epirubicine as second-line treatment for patients with advanced gastric cancer. Proc Am Clin Oncol 1999 ;18:277a (abst 1062).

 

de Gramont A, Maindrault-Goebel F, Louvet C, André T, Carola E, Gilles-Amar V, Izraël V, Krulik M. Evaluation of Oxaliplatin dose-intensity with the bimonthly 48H Leucovorin (LV) and 5-Fluorouracil (5FU) regimens (FOLFOX) in pretreated metastatic colorectal cancer. Proc Am Clin Oncol 1999 ;18:265a (abst 1018).

 

Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles-Amar V, Lotz JP, Izraël V, Krulik M. High-dose Oxaliplatin with the simplified 48H bimonthly Leucovorin (LV) and 5-Fluorouracil (5FU) regimen in pretreated metastatic colorectal cancer (FOLFOX7). Proc Am Clin Oncol 1999 ;18:265a (abst 1017).

 

Louvet C, Hammel P, André T, Vanica R, Landi B, Balosso J, Cattan S, Fonck M, Flesch M, Colin P, Gruson T, de Gramont A. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of Leucovorin, 5FU bolus and infusion, and Gemcitabine (FOLFUGEM Regimen). Proc Am Clin Oncol 1999 ;18:275a (abst 1054).

 

Molitor JL, de Gramont A, Louvet C, Demuynck B, Pigné A, Sezeur A, Cady J, Lagadec B, Milliez J, Krulik M. Long term survival after consolidation intraperitoneal chemotherapy in patients with advanced ovarian carcinoma in pathological compete response. 23rd Congress of the ESMO, 6-10 novembre 1998, Athènes.

 

André T, de Gramont A, Louvet C, Carola E, Maindrault-Goebel F, Couteau C, Krulik M, Izrael V. CPT11 with high-dose leucovorin and 5-Flurouracil 48 hour infusion in pretreated métastatic colorectal cancer (FOLFIRI). 23rd Congress of the ESMO, 6-10 novembre 1998, Athènes.

 

Tournigand C, de Gramont A, Louvet C, André T, Carola E, Gilles-Amar V, Maindrault-Goebel F, Lotz JP, Molitor JL, Ecstein-Fraisse E, Izrael V, Krulik M. A simplified bimonthly regimen with leucovorin and 5-Flurouracil for métastatic colorectal cancer . 23rd Congress of the ESMO, Athènes, 6-10 novembre 1998.

 

Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles-Amar V, Izrael V, Krulik M. Oxaliplatin with high-dose leucovorin and 5-Flurouracil 48 hour infusion in pretreated métastatic colorectal cancer (FOLFOX6). 23rd Congress of the ESMO, 6-10 novembre 1998, Athènes.

 

Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles-Amar V, Izraël V, Molitor JL, Krulik M. Bi-monthly Oxaliplatin with Leucovorin (LV) and 5-Fluorouracil (5FU) in pretreated metastatic colorecal cancer (FOLFOX6). Proc Am Clin Oncol 1998 ;17:273a (abst 1049).

 

André T, de Gramont A, Louvet C, Carola E, Lotz JP, Maindrault-Goebel F, Beerblock K, Izraël V, Krulik M. Bi-monthly CPT11 with Leucovorin (LV) and 5-Fluorouracil (5FU) in pretreated metastatic colorectal cancer (FOLFIRI). Proc Am Clin Oncol 1998 ;17:273a (abst 1051).

 

Tournigand C, de Gramont A, Louvet C, André T, Carola E, Gilles-Amar V, Maindrault-Goebel F, Lotz JP, Molitor JL, Izraël V, Ecstein-Fraisse E, Krulik M. A simplified bi-monthly regimen with Leucovorin (LV) ans 5-Fluorouracil (5FU) for metastatic colorectal cancer (MCRC). Proc Am Clin Oncol 1998 ;17:274a (abst 1051).

 

de Gramont A, Louvet C, André T, Demuynck B, Garcia M, Carola E, Krulik M, GERCOD, Hôpital Saint-Antoine. A simplified bimonthly regimen with Leucovorin (LV) and 5-Fluorouracil (5-FU) for metastatic colorectal cancer (MCRC). Proc Am Clin Oncol 1997 ;16:287a (abst 1019).
Accueil | | Nous contacter
© 2002 Gercor
Sitemap